Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Efficacy and Applicability of Chimeric Antigen Receptor (Car) T Cell-Based Regimens for Primary Bone Tumors: A Comprehensive Review of Current Evidence Publisher



Barzegari A1 ; Salemi F2 ; Kamyab A3 ; Aratikatla A4 ; Nejati N5 ; Valizade M6 ; Eltouny E7 ; Ebrahimi A7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Cell Science Research Center, Kian Immune Cell Co, Tehran, Iran
  2. 2. Hematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Faculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran
  4. 4. School of Medicine, Royal College of Surgeons in Ireland, County Dublin, Dublin, Ireland
  5. 5. Pediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Iran
  6. 6. School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  7. 7. Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

Source: Journal of Bone Oncology Published:2024


Abstract

Primary bone tumors (PBT), although rare, could pose significant mortality and morbidity risks due to their high incidence of lung metastasis. Survival rates of patients with PBTs may vary based on the tumor type, therapeutic interventions, and the time of diagnosis. Despite advances in the management of patients with these tumors over the past four decades, the survival rates seem not to have improved significantly, implicating the need for novel therapeutic interventions. Surgical resection with wide margins, radiotherapy, and systemic chemotherapy are the main lines of treatment for PBTs. Neoadjuvant and adjuvant chemotherapy, along with emerging immunotherapeutic approaches such as chimeric antigen receptor (CAR)-T cell therapy, have the potential to improve the treatment outcomes for patients with PBTs. CAR-T cell therapy has been introduced as an option in hematologic malignancies, with FDA approval for several CD19-targeting CAR-T cell products. This review aims to highlight the potential of immunotherapeutic strategies, specifically CAR T cell therapy, in managing PBTs. © 2024 The Author(s)
Related Docs
View other Related Docs
1. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)
2. Genetic Modification of Cytokine Signaling to Enhance Efficacy of Car T Cell Therapy in Solid Tumors, Frontiers in Immunology (2021)
3. Car T Cell Therapy in Solid Tumors; With an Extensive Focus on Obstacles and Strategies to Overcome the Challenges, International Immunopharmacology (2021)
4. Neurological Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy, Expert Review of Clinical Immunology (2023)
5. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells, Frontiers in Immunology (2018)
6. Therapeutic Roles of Car T Cells in Infectious Diseases: Clinical Lessons Learnt From Cancer, Reviews in Medical Virology (2022)
7. Cancer Stem Cell-Targeted Chimeric Antigen Receptor (Car)-T Cell Therapy: Challenges and Prospects, Acta Pharmaceutica Sinica B (2021)
8. Tumor Immunology, Clinical Immunology (2022)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (19)
Hamid Reza Mirzaei (15)
Other Related Docs
9. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications, Frontiers in Immunology (2017)
10. A Deep Insight Into Crispr/Cas9 Application in Car-T Cell-Based Tumor Immunotherapies, Stem Cell Research and Therapy (2021)
11. Car-Nk Cells for Haematological Cancers, Best Practice and Research: Clinical Haematology (2025)
12. Car-T Cells: Early Successes in Blood Cancer and Challenges in Solid Tumors, Acta Pharmaceutica Sinica B (2021)
13. Chimeric Antigen Receptor T-Cell Therapy for Breast Cancer, Future Oncology (2021)
14. Chimeric Antigen Receptor (Car) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead, Cells (2021)
15. Mitochondria As Playmakers of Car T-Cell Fate and Longevity, Cancer Immunology Research (2021)
16. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
17. An Updated Overview of the Application of Car-T Cell Therapy in Neurological Diseases, Biotechnology Progress (2023)
18. Crispr/Cas9 Revitalizes Adoptive T-Cell Therapy for Cancer Immunotherapy, Journal of Experimental and Clinical Cancer Research (2021)
19. Novel Car T Therapy Is a Ray of Hope in the Treatment of Seriously Ill Aml Patients, Stem Cell Research and Therapy (2021)
20. Car-Engineered Nk Cells Versus Car T Cells in Treatment of Glioblastoma; Strength and Flaws, Journal of Neuro-Oncology (2025)
21. Receptor Tyrosine Kinase-Like Orphan Receptor 1: A Novel Target for Cancer Immunotherapy, Expert Opinion on Therapeutic Targets (2015)
22. The Paths and Challenges of “Off-The-Shelf” Car-T Cell Therapy: An Overview of Clinical Trials, Biomedicine and Pharmacotherapy (2023)
23. T Cell Engineered With a Novel Nanobody-Based Chimeric Antigen Receptor Against Vegfr2 As a Candidate for Tumor Immunotherapy, IUBMB Life (2019)
24. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)
25. Programmable and Multi-Targeted Cars: A New Breakthrough in Cancer Car-T Cell Therapy, Clinical and Translational Oncology (2021)
26. A Metabolic Switch to Memory Car T Cells: Implications for Cancer Treatment, Cancer Letters (2021)
27. Chimeric Antigen Receptor -T Cell Therapy: Applications and Challenges in Treatment of Allergy and Asthma, Biomedicine and Pharmacotherapy (2020)
28. Car-Nk Cell: A New Paradigm in Tumor Immunotherapy, Frontiers in Oncology (2021)
29. Applications of Single-Cell Omics for Chimeric Antigen Receptor T Cell Therapy, Immunology (2024)
30. Car-Modified T-Cell Therapy for Cancer: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
31. Outsmarting Trogocytosis to Boost Car Nk/T Cell Therapy, Molecular Cancer (2023)
32. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
33. Genetically Modified Immune Cells Targeting Tumor Antigens, Pharmacology and Therapeutics (2020)
34. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
35. Exhaustion of T Lymphocytes in the Tumor Microenvironment: Significance and Effective Mechanisms, Cellular Immunology (2017)
36. Remote Controlling of Car-T Cells and Toxicity Management: Molecular Switches and Next Generation Cars, Translational Oncology (2021)
37. Crosstalk Between Autophagy and Metabolic Regulation of (Car) T Cells: Therapeutic Implications, Frontiers in Immunology (2023)
38. Spontaneous Immunity Against the Receptor Tyrosine Kinase Ror1 in Patients With Chronic Lymphocytic Leukemia, PLoS ONE (2015)
39. Exploring Cd19-Targeted Immunotherapy Strategies for Human B-Cell Lymphoma, Archives of Razi Institute (2025)
40. Recent Advances in Regenerative Medicine Strategies for Cancer Treatment, Biomedicine and Pharmacotherapy (2021)
41. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
42. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
43. Production of Car T-Cells by Gmp-Grade Lentiviral Vectors: Latest Advances and Future Prospects, Critical Reviews in Clinical Laboratory Sciences (2019)
44. Crispr, Car-T, and Nk: Current Applications and Future Perspectives, Genes and Diseases (2024)
45. The Potential Role of Immunotherapy in Wilms’ Tumor: Opportunities and Challenges, Current Pharmaceutical Design (2023)
46. The Role of Activated Leukocyte Cell Adhesion Molecule (Alcam) in Cancer Progression, Invasion, Metastasis and Recurrence: A Novel Cancer Stem Cell Marker and Tumor-Specific Prognostic Marker, Experimental and Molecular Pathology (2020)
47. Research Trends in Car-T Cell Therapy a Comprehensive Bibliometric Analysis Highlighting Cardiovascular Toxicity and Clinical Implications, Medicine (United States) (2025)
48. A Vhh-Based Anti-Muc1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to Muc1-Positive Cancer Cells, Cell Journal (2021)
49. Chimeric Antigen Receptor T-Cell Therapy for Melanoma, Expert Review of Clinical Immunology (2021)
50. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools, ACS Pharmacology and Translational Science (2023)